{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T10:40:39Z","timestamp":1777804839047,"version":"3.51.4"},"reference-count":21,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T00:00:00Z","timestamp":1734912000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T00:00:00Z","timestamp":1734912000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"Allergan","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Child Neurol"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>To evaluate the efficacy and safety of onabotulinumtoxinA for treating upper and lower limb spasticity among pediatric patients in 2 open-label extension trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients aged &lt;18 years received \u22645 doses of onabotulinumtoxinA (maximum: 8\u2005U\/kg [300 U], cycle 1; 10\u2005U\/kg [340 U], cycles 2-5) over 60 weeks. Week 6 efficacy endpoints included mean change from baseline in Modified Ashworth Scale\u2013Bohannon and Modified Tardieu Scale scores, and mean Clinical Global Impression of Overall Change score. Adverse events and laboratory assessments of bone health were monitored.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 580 patients received onabotulinumtoxinA. Modified Ashworth Scale\u2013Bohannon change from baseline ranged from \u22121.01 to \u22121.9. Modified Tardieu Scale change from baseline was 13.6 to 18.1 (ankle), 25.8 to 44.1 (elbow), and \u22125.0 to \u221226.3 (wrist). Clinical Global Impression of Overall Change scores were 1.5 to 2.2. The most common treatment-emergent adverse events were upper respiratory tract infection (16.9%) and nasopharyngitis (15.7%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interpretation<\/jats:title>\n                    <jats:p>Repeat administration of onabotulinumtoxinA was safe and efficacious for treating upper and lower limb spasticity in children.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/08830738241288431","type":"journal-article","created":{"date-parts":[[2024,12,24]],"date-time":"2024-12-24T02:28:21Z","timestamp":1735007301000},"page":"168-179","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy and Safety of OnabotulinumtoxinA for the Treatment of Pediatric Upper and Lower Limb Spasticity: Results From 2 Open-Label, Long-term Extension Trials"],"prefix":"10.1177","volume":"40","author":[{"given":"Mark","family":"Gormley","sequence":"first","affiliation":[{"name":"Department of Physical Medicine and Rehabilitation, Gillette Children's Specialty Healthcare, St. Paul, MN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Darcy","family":"Fehlings","sequence":"additional","affiliation":[{"name":"Holland Bloorview Kids Rehabilitation Hospital\/Department of Paediatrics, University of Toronto, Toronto, ON, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heakyung","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Physical Medicine and Rehabilitation, University of Texas Southwestern Medical Center, Dallas, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcin","family":"Bonikowski","sequence":"additional","affiliation":[{"name":"Department of Neurorehabilitation, MCN Zag\u00f3rze, Zag\u00f3rze, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Banach","sequence":"additional","affiliation":[{"name":"Department of Neurology, Jagiellonian University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatma","family":"Gul","sequence":"additional","affiliation":[{"name":"Department of Physical Medicine and Rehabilitation, University of Texas Southwestern Medical Center, Dallas, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jill","family":"Meilahn","sequence":"additional","affiliation":[{"name":"Department of Physical Medicine and Rehabilitation, Marshfield Clinic Health System, Marshfield, WI, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brad","family":"Racette","sequence":"additional","affiliation":[{"name":"Barrow Neurological Institute"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nuoyu","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Pharmacovigilance and Patient Safety, Allergan, an AbbVie Company, Madison, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaomeng","family":"Niu","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Allergan, an AbbVie Company, Madison, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2527-2187","authenticated-orcid":false,"given":"Lynn M.","family":"James","sequence":"additional","affiliation":[{"name":"Department of Global Development, Allergan, an AbbVie Company, Irvine, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rozalina","family":"Dimitrova","sequence":"additional","affiliation":[{"name":"Department of Global Development, Allergan, an AbbVie Company, Irvine, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2024,12,23]]},"reference":[{"key":"e_1_3_3_2_2","first-page":"487","volume-title":"Spasticity: disordered motor control","author":"Lance JW","year":"1980","unstructured":"Lance JW. Symposium synopsis: the stretch reflex arc. In: Feldman RG, Young RR, Koella WP, eds. Spasticity: disordered motor control. Symposia Specialists; 1980:487-489."},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/27.2.239"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.3109\/09638288.2011.641662"},{"issue":"109","key":"e_1_3_3_5_2","first-page":"1","article-title":"The definition and classification of cerebral palsy","volume":"49","year":"2007","unstructured":"The definition and classification of cerebral palsy. Dev Med Child Neurol. 2007;49(s109):1-44.","journal-title":"Dev Med Child Neurol"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-8749.2007.00751.x"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-8749.2010.03844.x"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/mus.24763"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1177\/088307380101600104"},{"issue":"4","key":"e_1_3_3_10_2","first-page":"213","article-title":"Cerebral palsy: an overview","volume":"101","author":"Vitrikas K","year":"2020","unstructured":"Vitrikas K, Dalton H, Breish D. Cerebral palsy: an overview. Am Fam Physician. 2020;101(4):213-220.","journal-title":"Am Fam Physician"},{"issue":"1","key":"e_1_3_3_11_2","article-title":"Botulinum toxin A as an adjunct to treatment in the management of the upper limb in children with spastic cerebral palsy (UPDATE)","volume":"2010","author":"Hoare BJ","year":"2010","unstructured":"Hoare BJ, Wallen MA, Imms C, Villanueva E, Rawicki HB, Carey L. Botulinum toxin A as an adjunct to treatment in the management of the upper limb in children with spastic cerebral palsy (UPDATE). Cochrane Database Syst Rev. 2010;2010(1):CD003469.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1097\/01241398-199405000-00005"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.3233\/NRE-210071"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.3233\/NRE-210070"},{"issue":"4","key":"e_1_3_3_15_2","article-title":"Objective measurement of clinical findings in the use of botulinum toxin type A for the management of children with cerebral palsy","volume":"6","author":"Boyd RN","year":"1999","unstructured":"Boyd RN, Graham HK. Objective measurement of clinical findings in the use of botulinum toxin type A for the management of children with cerebral palsy. Eur J Neurol. 1999;6(S4):s23-s35.","journal-title":"Eur J Neurol"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/dmcn.12178"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1080\/13638490600668061"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12887-020-02122-9"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.2106\/JBJS.RVW.18.00153"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/dmcn.12200"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/dmcn.13988"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.3390\/toxins13120889"}],"container-title":["Journal of Child Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/08830738241288431","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/08830738241288431","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/08830738241288431","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T20:41:21Z","timestamp":1777495281000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/08830738241288431"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,23]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["10.1177\/08830738241288431"],"URL":"https:\/\/doi.org\/10.1177\/08830738241288431","relation":{},"ISSN":["0883-0738","1708-8283"],"issn-type":[{"value":"0883-0738","type":"print"},{"value":"1708-8283","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,23]]}}}